CAC Nantong Chemical Co. Ltd. Class A

CAC Nantong Chemical Co. Ltd. Class A

SSZSE:301665
19.02
CNY
-0.04
(-0.21%)
1.25EPS
22.00P/E
9.91BMarket Cap
May 03Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.31
5.95
7.68
7.54
8.81
12.57
9.6
10.51
12.33
12.97
Basic EPS, GAAP
0.33
0.96
1.31
0.97
0.98
1.6
0.86
0.66
1.07
1
Free Cash Flow per Basic Share
0.14
0.6
0.75
0.46
-0.97
-0.33
-0.56
-1.43
-0.21
- -
Dividend per Share
0.25
0.18
0.46
0.85
0.12
0.93
0.18
0.16
0.79
0.71
Book Value per Share
1.83
2.73
3.84
4.05
5.03
5.93
6.79
7.47
8.01
8.2
Tangible Book Value per Share
1.51
2.42
3.52
3.58
4.54
5.42
6.25
6.94
7.21
7.42
Basic Weighted Avg Shares
408
403
404
405
406
406
403
403
435
449
Sales/Revenue/Turnover
1,759
2,396
3,105
3,058
3,579
5,099
3,868
4,236
5,369
5,828
Operating Margin (%)
15.94
25.31
29.39
22.3
15.3
17.04
11.23
9.68
14.5
13.5
Depreciation Expense
87
94
122
144
160
202
222
241
259
- -
Net Income, GAAP
135
387
530
393
398
649
346
266
466
450
Effective Tax Rate (%)
17.99
16.37
15.26
13.91
10.72
14.03
11.48
10.14
13.19
12.27
Profit Margin (%)
7.66
16.15
17.06
12.86
11.12
12.73
8.96
6.28
8.68
7.72
Working Capital
-144
51
500
197
420
659
402
636
735
739
LT Debt
104
67
208
168
272
328
396
500
335
385
Total Equity
879
1,338
1,952
2,043
2,471
2,823
3,165
3,463
4,152
4,257
Return on Invested Capital (%)
- -
28.11
33.36
20.11
14.32
18.65
8.61
6.53
11.94
10.27
Return on Capital (%)
- -
22.8
21.18
15.9
18.36
23.1
12.92
7.97
7.19
7.13
Return on Common Equity (%)
- -
41.85
39.78
24.61
21.65
29.26
13.45
9.21
14.05
12.66

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
996
948
849
LT Borrowings
312
372
385
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
450
450
450
Market Capitalization
11,732
9,432
9,914

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,802
2,607
2,394
Cash, Cash Equivalents & STI
741
600
445
Accounts Receivable, Net
910
924
889
Inventories
908
888
776
Total Current Liabilities
2,018
1,819
1,655
Payables & Accruals
- -
- -
- -
ST Debt
996
948
849
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.33%
19.87%
Free Cash Flow
- -
-47.7%
-84.28%
Net Income, GAAP
- -
13.91%
75.13%
Sales/Revenue/Turnover
- -
14.32%
26.73%
Total Cash Common Dividend
- -
185.27%
414.21%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
871
1,088
1,064
1,213
4,236
2025
1,033
1,380
- -
1,478
5,369
2026
1,378
1,596
1,376
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
0.12
0.14
0.25
0.66
2025
0.19
0.23
- -
0.22
1.07
2026
0.3
0.24
0.25
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.04
- -
- -
0.16
2025
0.04
0.44
- -
0.03
0.79
2026
0.04
0.44
0.2
- -
- -

Company Description

CEO
Xiao Hong Tian
Full Time Employees
2,711
Sector
Process industries
Industry
Chemicals: agricultural
Address
Building 5 Nantong JS China 200 335
IPO Date
Apr 11, 2025
Website
cacch.com
Business
CAC Nantong Chemical Co Ltd (301665.SZ) manufactures and sells specialty chemical products, primarily focusing on pharmaceutical intermediates, pesticide intermediates, and fine chemicals. The company offers a range of products including 2,5-dichloronitrobenzene, 2-chloro-5-nitrobenzotrifluoride, 4-chloro-3-nitrobenzotrifluoride, 2,4-dichloro-5-nitrobenzotrifluoride, and other fluorinated and chlorinated aromatic compounds used in agrochemicals, pharmaceuticals, and dyes; it also provides custom synthesis services and contract manufacturing for chemical intermediates. Headquartered in Nantong, Jiangsu Province, China, the company was founded in 2003 and operates primarily in the domestic Chinese market with exports to Asia and Europe. In recent developments, CAC Nantong Chemical expanded its production capacity through a new facility in 2024 for fluorinated intermediates to meet growing demand in the pharmaceutical sector; it also formed a strategic partnership with a leading agrochemical firm in early 2025 for joint development of pesticide intermediates and secured a RMB 150 million funding round for technology upgrades. The company serves major producers in the agrochemical and pharmaceutical industries as its target customers, with no listed subsidiaries or parent relationships.